Antithrombin III improved neutrophil extracellular traps in lung after the onset of endotoxemia

Michiko Ishikawa, Hayato Yamashita, Nobuki Oka, Takahiro Ueda, Keisuke Kohama, Atsunori Nakao, Joji Kotani

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background Coagulation and inflammation are closely linked during acute inflammatory conditions, such as sepsis. Antithrombin (AT) is an anticoagulant that also has anti-inflammatory activities. The effects of therapeutically administering AT III after the onset of endotoxemia or sepsis were not clear. Here, we studied the effects of administering AT III after inducing lethal endotoxemia in mice. Methods Mice were injected intraperitoneally with lipopolysaccharide (LPS) to induce endotoxemia. AT III was administered 3 h later. We assessed survival and the severity of endotoxemia and quantified plasma cytokine levels and biochemical markers of liver and kidney function. In the lungs, we examined neutrophil accumulation, neutrophil extracellular traps, alveolar wall thickness, and chemokine (C-X-C motif) ligand 1 (cxcl-1), cxcl-2, and high mobility group box 1 expression. Results Administering AT III reduced the severity and mortality of LPS-induced endotoxemia as indicated by 24-h survival of 84% of the mice that received LPS + AT III and only 53% of mice given LPS alone (P < 0.05). AT III treatment attenuated several changes induced in the lungs by endotoxemia including cxcl-2 mRNA expression, high mobility group box 1 protein expression, neutrophil accumulation, alveolar septal thickening, and neutrophil extracellular trap formation. AT III did not decrease plasma cytokine levels or plasma urea nitrogen levels that were upregulated as a result of LPS-induced endotoxemia. Conclusions Administration of AT III after the onset of endotoxemia improved outcomes in a mouse model. The attenuation of lung inflammation may have a large impact on mortality and morbidity. Because lung inflammation increases the likelihood of mortality from sepsis, AT III could be a useful agent in septic patients.

Original languageEnglish
Pages (from-to)140-150
Number of pages11
JournalJournal of Surgical Research
Volume208
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Antithrombin III
Endotoxemia
Lung
Lipopolysaccharides
Sepsis
Mortality
Pneumonia
Chemokine CXCL1
Neutrophils
Cytokines
HMGB1 Protein
Extracellular Traps
Survival
Antithrombins
Anticoagulants
Urea
Anti-Inflammatory Agents
Nitrogen
Biomarkers
Inflammation

Keywords

  • Anti-Inflammation
  • Antithrombin
  • HMGB-1
  • Lung
  • Neutrophil extracellular traps
  • Sepsis

ASJC Scopus subject areas

  • Surgery

Cite this

Antithrombin III improved neutrophil extracellular traps in lung after the onset of endotoxemia. / Ishikawa, Michiko; Yamashita, Hayato; Oka, Nobuki; Ueda, Takahiro; Kohama, Keisuke; Nakao, Atsunori; Kotani, Joji.

In: Journal of Surgical Research, Vol. 208, 01.02.2017, p. 140-150.

Research output: Contribution to journalArticle

Ishikawa, Michiko ; Yamashita, Hayato ; Oka, Nobuki ; Ueda, Takahiro ; Kohama, Keisuke ; Nakao, Atsunori ; Kotani, Joji. / Antithrombin III improved neutrophil extracellular traps in lung after the onset of endotoxemia. In: Journal of Surgical Research. 2017 ; Vol. 208. pp. 140-150.
@article{417d9e543bef44298474cc7b032e9eca,
title = "Antithrombin III improved neutrophil extracellular traps in lung after the onset of endotoxemia",
abstract = "Background Coagulation and inflammation are closely linked during acute inflammatory conditions, such as sepsis. Antithrombin (AT) is an anticoagulant that also has anti-inflammatory activities. The effects of therapeutically administering AT III after the onset of endotoxemia or sepsis were not clear. Here, we studied the effects of administering AT III after inducing lethal endotoxemia in mice. Methods Mice were injected intraperitoneally with lipopolysaccharide (LPS) to induce endotoxemia. AT III was administered 3 h later. We assessed survival and the severity of endotoxemia and quantified plasma cytokine levels and biochemical markers of liver and kidney function. In the lungs, we examined neutrophil accumulation, neutrophil extracellular traps, alveolar wall thickness, and chemokine (C-X-C motif) ligand 1 (cxcl-1), cxcl-2, and high mobility group box 1 expression. Results Administering AT III reduced the severity and mortality of LPS-induced endotoxemia as indicated by 24-h survival of 84{\%} of the mice that received LPS + AT III and only 53{\%} of mice given LPS alone (P < 0.05). AT III treatment attenuated several changes induced in the lungs by endotoxemia including cxcl-2 mRNA expression, high mobility group box 1 protein expression, neutrophil accumulation, alveolar septal thickening, and neutrophil extracellular trap formation. AT III did not decrease plasma cytokine levels or plasma urea nitrogen levels that were upregulated as a result of LPS-induced endotoxemia. Conclusions Administration of AT III after the onset of endotoxemia improved outcomes in a mouse model. The attenuation of lung inflammation may have a large impact on mortality and morbidity. Because lung inflammation increases the likelihood of mortality from sepsis, AT III could be a useful agent in septic patients.",
keywords = "Anti-Inflammation, Antithrombin, HMGB-1, Lung, Neutrophil extracellular traps, Sepsis",
author = "Michiko Ishikawa and Hayato Yamashita and Nobuki Oka and Takahiro Ueda and Keisuke Kohama and Atsunori Nakao and Joji Kotani",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.jss.2016.09.041",
language = "English",
volume = "208",
pages = "140--150",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Antithrombin III improved neutrophil extracellular traps in lung after the onset of endotoxemia

AU - Ishikawa, Michiko

AU - Yamashita, Hayato

AU - Oka, Nobuki

AU - Ueda, Takahiro

AU - Kohama, Keisuke

AU - Nakao, Atsunori

AU - Kotani, Joji

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background Coagulation and inflammation are closely linked during acute inflammatory conditions, such as sepsis. Antithrombin (AT) is an anticoagulant that also has anti-inflammatory activities. The effects of therapeutically administering AT III after the onset of endotoxemia or sepsis were not clear. Here, we studied the effects of administering AT III after inducing lethal endotoxemia in mice. Methods Mice were injected intraperitoneally with lipopolysaccharide (LPS) to induce endotoxemia. AT III was administered 3 h later. We assessed survival and the severity of endotoxemia and quantified plasma cytokine levels and biochemical markers of liver and kidney function. In the lungs, we examined neutrophil accumulation, neutrophil extracellular traps, alveolar wall thickness, and chemokine (C-X-C motif) ligand 1 (cxcl-1), cxcl-2, and high mobility group box 1 expression. Results Administering AT III reduced the severity and mortality of LPS-induced endotoxemia as indicated by 24-h survival of 84% of the mice that received LPS + AT III and only 53% of mice given LPS alone (P < 0.05). AT III treatment attenuated several changes induced in the lungs by endotoxemia including cxcl-2 mRNA expression, high mobility group box 1 protein expression, neutrophil accumulation, alveolar septal thickening, and neutrophil extracellular trap formation. AT III did not decrease plasma cytokine levels or plasma urea nitrogen levels that were upregulated as a result of LPS-induced endotoxemia. Conclusions Administration of AT III after the onset of endotoxemia improved outcomes in a mouse model. The attenuation of lung inflammation may have a large impact on mortality and morbidity. Because lung inflammation increases the likelihood of mortality from sepsis, AT III could be a useful agent in septic patients.

AB - Background Coagulation and inflammation are closely linked during acute inflammatory conditions, such as sepsis. Antithrombin (AT) is an anticoagulant that also has anti-inflammatory activities. The effects of therapeutically administering AT III after the onset of endotoxemia or sepsis were not clear. Here, we studied the effects of administering AT III after inducing lethal endotoxemia in mice. Methods Mice were injected intraperitoneally with lipopolysaccharide (LPS) to induce endotoxemia. AT III was administered 3 h later. We assessed survival and the severity of endotoxemia and quantified plasma cytokine levels and biochemical markers of liver and kidney function. In the lungs, we examined neutrophil accumulation, neutrophil extracellular traps, alveolar wall thickness, and chemokine (C-X-C motif) ligand 1 (cxcl-1), cxcl-2, and high mobility group box 1 expression. Results Administering AT III reduced the severity and mortality of LPS-induced endotoxemia as indicated by 24-h survival of 84% of the mice that received LPS + AT III and only 53% of mice given LPS alone (P < 0.05). AT III treatment attenuated several changes induced in the lungs by endotoxemia including cxcl-2 mRNA expression, high mobility group box 1 protein expression, neutrophil accumulation, alveolar septal thickening, and neutrophil extracellular trap formation. AT III did not decrease plasma cytokine levels or plasma urea nitrogen levels that were upregulated as a result of LPS-induced endotoxemia. Conclusions Administration of AT III after the onset of endotoxemia improved outcomes in a mouse model. The attenuation of lung inflammation may have a large impact on mortality and morbidity. Because lung inflammation increases the likelihood of mortality from sepsis, AT III could be a useful agent in septic patients.

KW - Anti-Inflammation

KW - Antithrombin

KW - HMGB-1

KW - Lung

KW - Neutrophil extracellular traps

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=84992197925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992197925&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2016.09.041

DO - 10.1016/j.jss.2016.09.041

M3 - Article

C2 - 27993201

AN - SCOPUS:84992197925

VL - 208

SP - 140

EP - 150

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

ER -